WALTHAM, Mass., May 02, 2023 (GLOBE NEWSWIRE) — Repligen Corporation ( NASDAQ:RGEN ), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first fiscal quarter ended March 31, 2023. Provided in this press release are financial highlights for the quarter, updates to our financial guidance for the year 2023 and access information for today's webcast and conference call.